![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC36A1 |
Gene summary for SLC36A1 |
![]() |
Gene information | Species | Human | Gene symbol | SLC36A1 | Gene ID | 206358 |
Gene name | solute carrier family 36 member 1 | |
Gene Alias | Dct1 | |
Cytomap | 5q33.1 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q7Z2H8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
206358 | SLC36A1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.28e-10 | 5.20e-01 | -0.1954 |
206358 | SLC36A1 | A002-C-205 | Human | Colorectum | FAP | 8.13e-03 | -1.53e-01 | -0.1236 |
206358 | SLC36A1 | A015-C-006 | Human | Colorectum | FAP | 4.07e-04 | -2.05e-01 | -0.0994 |
206358 | SLC36A1 | A002-C-116 | Human | Colorectum | FAP | 5.03e-04 | -1.61e-01 | -0.0452 |
206358 | SLC36A1 | A014-C-008 | Human | Colorectum | FAP | 1.08e-03 | -2.05e-01 | -0.191 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1902600 | Colorectum | AD | proton transmembrane transport | 66/3918 | 157/18723 | 1.59e-09 | 1.17e-07 | 66 |
GO:19026004 | Colorectum | FAP | proton transmembrane transport | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC36A1 | SNV | Missense_Mutation | novel | c.1287N>C | p.Met429Ile | p.M429I | Q7Z2H8 | protein_coding | tolerated(0.23) | benign(0.006) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
SLC36A1 | SNV | Missense_Mutation | c.946N>T | p.Ala316Ser | p.A316S | Q7Z2H8 | protein_coding | tolerated(0.49) | benign(0.042) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
SLC36A1 | SNV | Missense_Mutation | novel | c.347A>T | p.Tyr116Phe | p.Y116F | Q7Z2H8 | protein_coding | tolerated(0.14) | probably_damaging(0.994) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD |
SLC36A1 | SNV | Missense_Mutation | c.1001N>T | p.Ser334Leu | p.S334L | Q7Z2H8 | protein_coding | tolerated(0.35) | benign(0.232) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
SLC36A1 | insertion | Frame_Shift_Ins | novel | c.1391dupA | p.Asn464LysfsTer66 | p.N464Kfs*66 | Q7Z2H8 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SLC36A1 | SNV | Missense_Mutation | novel | c.1252C>T | p.Leu418Phe | p.L418F | Q7Z2H8 | protein_coding | deleterious(0.05) | benign(0.167) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC36A1 | SNV | Missense_Mutation | rs749715139 | c.1184N>A | p.Arg395His | p.R395H | Q7Z2H8 | protein_coding | tolerated(0.12) | benign(0.177) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC36A1 | SNV | Missense_Mutation | rs758625230 | c.1042N>A | p.Ala348Thr | p.A348T | Q7Z2H8 | protein_coding | tolerated(0.11) | benign(0.409) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC36A1 | SNV | Missense_Mutation | c.619C>A | p.Leu207Met | p.L207M | Q7Z2H8 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC36A1 | SNV | Missense_Mutation | novel | c.721C>G | p.Gln241Glu | p.Q241E | Q7Z2H8 | protein_coding | deleterious(0.02) | benign(0.158) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 135651515 | TRYPTOPHAN | |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 135651413 | SEROTONIN | |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 178101420 | ||
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 178101386 | OXITRIPTAN |
Page: 1 |